orka-001
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2025 (NCT06698939)
Timeline
Indications
Mechanism of action
- Interleukin-37INHIBITOR
IL37 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07290569 | Phase 2 | Dec 3, 2025 | Oruka Therapeutics, Inc. |
| NCT07090330 | Phase 2 | Jul 18, 2025 | Oruka Therapeutics, Inc. |
| NCT06698939 | Phase 1 | Mar 31, 2025 | Oruka Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oruka Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2025 |
1 organizations
Page 1 / 1